PTC Therapeutics To Participate At Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J., March 1, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:

    --  Cowen and Company 38(th )Annual Health Care Conference, on Wednesday,
        March 14th at 8:00 a.m. ET
    --  Barclays Global Healthcare Conference 2018, on Thursday, March 15(th),
        at 9:00 a.m. ET

The presentations will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. PTC's current Investor Presentation are available at the same website location.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines using our expertise in RNA biology. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. Since its founding 20 years ago, PTC's mission has focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey. For more information on the company, please visit our website www.ptcbio.com.


    FOR MORE INFORMATION PLEASE CONTACT:


    Media:                               Investors:

    Jane Baj                             Emily Hill

    +1 (908) 912-9167                                     +1 (908) 912-9327

    jbaj@ptcbio.com                      ehill@ptcbio.com

View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-300606284.html

SOURCE PTC Therapeutics, Inc.